<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-C
Report by Issuer of Securities Quoted on NASDAQ
Interdealer Quotation System
Filed pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 and Rule 13a-17
or 15d-17 thereunder
GENZYME CORPORATION
- --------------------------------------------------------------------------------
(Exact name of issuer as specified in charter)
One Kendall Square, Cambridge, Massachusetts 02139
- --------------------------------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code: (617) 252-7500
----------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number
of shares outstanding:
1. Title of Security: TISSUE REPAIR DIVISION COMMON STOCK, $0.01 PAR VALUE
2. Number of shares outstanding before the change: 8,818,362 AS OF JUNE 30, 1995
3. Number of shares outstanding after the change: 11,818,362
4. Effective date of change: SEPTEMBER 27, 1995
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution,
stock split, reverse split, acquisition of stock for treasury, etc.): PUBLIC
OFFERING.
Give brief description of transaction:
(1) ISSUANCE OF 3,000,000 SHARES IN UNDERWRITTEN PUBLIC OFFERING, WITH
AN ADDITIONAL 450,000 SHARES RESERVED FOR UNDERWRITERS' OVER-ALLOTMENTS.
II. CHANGE IN NAME OF ISSUER
Not Applicable
Date: September 27, 1995 /s/ Evan M. Lebson
------------------------------------
Name: Evan M. Lebson
Title: Vice President, Treasurer
